Refractec's ViewPoint System May Provide Alternative To LASIK Surgery
This article was originally published in The Gray Sheet
Executive Summary
FDA's Ophthalmic Devices Panel review of Refractec's ViewPoint conductive keratoplasty system to treat spherical hyperopia in patients over 40 has been rescheduled for Nov. 30.
You may also be interested in...
Refractec ViewPoint Approval Should Reflect Lack Of Long-Term Data – Panel
Refractec should modify the proposed labeling for its ViewPoint conductive keratoplasty system to reflect a dearth of long-term efficacy data, FDA's Ophthalmic Devices Panel recommended Nov. 30 in voting 9-1 for the device's approval
Refractec ViewPoint Approval Should Reflect Lack Of Long-Term Data – Panel
Refractec should modify the proposed labeling for its ViewPoint conductive keratoplasty system to reflect a dearth of long-term efficacy data, FDA's Ophthalmic Devices Panel recommended Nov. 30 in voting 9-1 for the device's approval
Overseas Inspections Grounded For September, Could Resume In October
FDA expects to resume international inspections in October, according to Office of Regulatory Affairs staffers.